Fidson Healthcare Plc, Nigeria’s leading pharmaceutical company, has recently entered into a Strategic Cooperation Memorandum with Jiangsu Aidea Pharma, Nanjing PharmaBlock, and the China-Africa Development Fund in Beijing, China. The signing ceremony took place during a significant visit led by Dr. Fidelis Ayebae, the Founder and Managing Director of Fidson Healthcare. The Nigerian delegation also included Dr. Babatunde Ipaye and Mr. Oshoke Ayebae.
This collaboration marks a pivotal step in enhancing Africa’s self-reliance in healthcare delivery, particularly in the fight against HIV. The four parties will leverage their unique strengths to establish a new joint venture pharmaceutical plant in Nigeria. This initiative aims to not only boost local pharmaceutical manufacturing but also ensure the availability of essential medications for the continent. As part of the agreement, the parties will share information and resources, explore investment opportunities in the West African pharmaceutical market, and implement cooperative investments at the project level. This partnership promises to strengthen healthcare systems across the region, making significant strides towards improved access to vital medications for all Africans.
Read Also: Edo election: Don’t wear campaign attire to polling units, INEC warns parties, supporters
This signing ceremony follows a series of engagements, including a visit by the Chairman of Jiangsu Aidea Pharma, Dr. Heliang Fu, to Nigeria earlier in the year. During that visit, Dr. Fu toured the Lekki Free Trade Zone, which is the chosen site for the state-of-the-art manufacturing facility set to revolutionise the pharmaceutical industry in Nigeria and the wider African continent. The partnership between Fidson and the Chinese firms exemplifies international cooperation aimed at tackling pressing medical challenges. The upcoming manufacturing facility will become a hub for pharmaceutical excellence, leveraging the Lekki Free Trade Zone’s strategic location and comprehensive infrastructure to foster economic growth and healthcare improvement. In the words of Dr. Fu, “This collaboration marks an important step for Chinese pharmaceutical players in their commitment to global medical cooperation. By integrating our expertise and experience in the field of innovative drugs, we are confident in bringing greater well-being to African patients.”
Dr. Ayebae expressed his optimism about the partnership, stating, “We eagerly look forward to this collaboration and believe that the complementary strengths of all parties will inject new vitality into the healthcare delivery sector in Africa, particularly addressing the medical needs of over 1.9 million HIV-infected individuals in Nigeria, which is a focus of Aidea Pharma.” He added that the project is coming at a timely moment, as the National Agency for the Control of AIDS (NACA) in Nigeria, under the leadership of Dr. Temitope Ilori, champions the government’s drive to provide necessary support and create an enabling environment for pharmaceutical companies to initiate local production of Anti-Retroviral drugs (ARVs).